News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genitope Corporation (GTOP)'s MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial Results Available on Company Website


4/9/2008 8:30:13 AM

FREMONT, Calif.--(BUSINESS WIRE)--Genitope Corporation (Genitope, NASDAQ: GTOP) today announced that a summary of the data from its pivotal Phase 3 clinical trial examining the use of MyVax® personalized immunotherapy (MyVax) in previously untreated follicular B-cell non-Hodgkin’s lymphoma (fNHL) patients is available on the Investor Relations section of Genitope’s Web site at http://ir.genitope.com. In December 2007, Genitope obtained data indicating that its pivotal Phase 3 clinical trial did not meet its primary endpoint. The primary analysis demonstrated that there was no statistically significant difference in the progression-free survival (PFS) of patients receiving MyVax compared to patients receiving a non-specific control immunotherapy. However, analysis of a pre-specified endpoint in the group of patients receiving MyVax showed a highly statistically significant difference in PFS between patients who mounted a positive immune response to the tumor-specific target and those who did not.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES